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Introduction
Personalizing treatment to “molecular phenotypes,” i.e., to subsets 
of patients with shared underlying biology, is an emerging strategy 
to guide therapeutic choices in chronic disease (1, 2). In respirato-
ry disease, this strategy has particularly gained traction in severe 
asthma, where subgroups of patients with type 2 and eosinophilic 
inflammation can be targeted using new biologics (1–4). Much of the 
inflammation in chronic respiratory disorders, however, does not 
BACKGROUND. Chronic obstructive pulmonary disease (COPD) is a heterogeneous smoking-related disease characterized by 
airway obstruction and inflammation. This inflammation may persist even after smoking cessation and responds variably to 
corticosteroids. Personalizing treatment to biologically similar “molecular phenotypes” may improve therapeutic efficacy in 
COPD. IL-17A is involved in neutrophilic inflammation and corticosteroid resistance, and thus may be particularly important in 
a COPD molecular phenotype.
METHODS. We generated a gene expression signature of IL-17A response in bronchial airway epithelial brushings from 
smokers with and without COPD (n = 238), and validated it using data from 2 randomized trials of IL-17 blockade in 
psoriasis. This IL-17 signature was related to clinical and pathologic characteristics in 2 additional human studies of COPD: 
(a) SPIROMICS (n = 47), which included former and current smokers with COPD, and (b) GLUCOLD (n = 79), in which COPD 
participants were randomized to placebo or corticosteroids.
RESULTS. The IL-17 signature was associated with an inflammatory profile characteristic of an IL-17 response, including 
increased airway neutrophils and macrophages. In SPIROMICS the signature was associated with increased airway obstruction 
and functional small airways disease on quantitative chest CT. In GLUCOLD the signature was associated with decreased 
response to corticosteroids, irrespective of airway eosinophilic or type 2 inflammation.
CONCLUSION. These data suggest that a gene signature of IL-17 airway epithelial response distinguishes a biologically, 
radiographically, and clinically distinct COPD subgroup that may benefit from personalized therapy.
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Here we studied the transcriptional response of the airway 
epithelium to IL-17. We have found that direct measurement of 
interleukin proteins, including IL-17, can be difficult in human 
blood and bronchoalveolar lavage fluid (23, 24). These challeng-
es may contribute to the inconsistent evidence for IL-17 protein 
levels being increased in COPD (25–30). Conversely, airway epi-
thelial cells have reproducible transcriptional responses to many 
interleukins. Thus our general strategy has been to assay this epi-
thelial response, which we have validated for IL-13 (24, 31, 32) and 
interferons (33).
We examined a genomic signature of the airway epithelial 
IL-17 response in 3 separate human COPD studies in which bron-
chial airway samples were collected during bronchoscopy. We first 
fit the IL-17 genomic signature, generated using bronchial epithe-
lial cells exposed to IL-17, to a cross-sectional study of ever-smok-
ers with and without COPD (bronchial airway epithelial [BAE] 
data set, n = 237). We next established that the signature specifi-
cally identified IL-17–associated inflammation by determining its 
response to other airway epithelial adaptive immune responses 
(types 1 and 2) and to IL-17–directed biologic therapies in psoriat-
ic skin lesions. We then tested the associations between this IL-17 
signature and clinical features in 2 independent COPD studies 
that collected rich phenotypic data (GLUCOLD, n = 79, and SPI-
ROMICS, n = 47; study design in Figure 1). We hypothesized that 
our airway epithelial IL-17 genomic signature would be increased 
in a COPD subset, and associated with distinct clinical, patholog-
ic, and radiographic characteristics.
Results
Generation of an airway epithelial IL-17–associated gene expression 
signature in COPD. We first characterized the airway epithelial 
response to IL-17 using whole transcriptome profiling of IL-17–
stimulated versus matched unstimulated control human bronchial 
epithelial cell (HBEC) cultures grown at air-liquid interface (ALI). 
The 100 genes most upregulated by log2 fold change in response to 
IL-17 were studied as candidate IL-17 signature genes.
We examined these 100 genes in a previously generated 
BAE transcriptome profiling data set derived from bronchoscop-
ic brushing samples from ever-smokers with (n = 85) and without 
respond to therapies directed against type 2 inflammation. Identify-
ing subgroups that display enhanced non–type 2 inflammatory path-
ways may lead to the repurposing of available biologics indicated for 
other inflammatory disorders to target these subgroups.
Chronic obstructive pulmonary disease (COPD) is a highly 
prevalent respiratory disease, most commonly associated with 
smoking. COPD is a major cause of morbidity and mortality 
worldwide for which few interventions have been found that pre-
vent disease progression (5). Yet molecular phenotyping has been 
less studied in COPD than in asthma and has focused on eosino-
philic and type 2 inflammation based on the previous work in asth-
ma (2). Type 2 inflammation is likely relevant in only a minority of 
COPD patients (6). Nonetheless, this work suggests that biolog-
ically distinct COPD subgroups exist and are clinically relevant. 
COPD patients with high eosinophil counts or an airway epithe-
lial genomic signature of type 2 inflammation are more likely to 
respond to corticosteroids, and potentially to biologics targeting 
eosinophils (6–9). These studies suggest the promise of molecular 
phenotyping in COPD, but responses beyond type 2 inflammation 
require further investigation.
The IL-17 family of cytokines includes 6 members that play 
various roles in mucosal host defense and chronic inflammation 
(10). IL-17A stimulates the airway epithelium to produce chemo-
kines and other mediators, which recruit and activate neutrophils 
and macrophages, cells crucial to COPD pathogenesis (11). IL-17A 
is implicated in COPD-associated pathogenic responses, including 
emphysema, lymphoid neogenesis, corticosteroid resistance, dys-
biosis, mucus hypersecretion, and ongoing inflammation despite 
smoking cessation (12–19). However, many of these responses 
have not been investigated in human studies. By identifying the 
COPD subgroup that manifests IL-17A–associated inflammation 
(IL-17A is hereafter referred to as IL-17), we hypothesize that we 
can distinguish a corticosteroid-unresponsive subgroup that may 
benefit from anti–IL-17 biologics. Anti–IL-17 biologics are now 
approved for the treatment of autoimmune diseases, specifically 
psoriasis and psoriatic arthritis, and are being studied in COPD 
(20, 21). Nontargeted trials of biologic therapies in COPD have 
failed to meet clinical endpoints, suggesting the importance of 
directing therapy to appropriate subgroups (22).
Figure 1. Study design. ALI, air-liquid interface; BAE, bronchial airway epithelial; BEC, bronchial epithelial cell; ICS, inhaled corticosteroid; RNA-Seq,  
RNA sequencing; T1, type 1 inflammation; T2, type 2 inflammation.
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potential biological relevance, independent of outcomes of inter-
est. We confirmed that the 10 genes selected by elastic net and 
CCL20 were all intercorrelated (Supplemental Figure 2), veri-
fying that the elastic net procedure removed loosely correlated 
genes. Nearly all of the 10 genes have previously been shown to 
be associated with IL-17–related inflammation (38–42). We thus 
used these 10 genes, along with CCL20, to construct a gene sig-
nature of airway epithelial response to IL-17 using the mean of 
their zero-centered log2 expression values.
We confirmed that the genes selected for the signature were 
measuring an IL-17 response not just specific to CCL20 in two ways. 
First, we evaluated the correlation between our IL-17 signature and 
a 5-gene airway epithelial IL-17 gene expression metric previous-
ly examined in asthma (39). In the BAE data set the 2 signatures 
were well correlated (ρ = 0.51, P < 2.2 × 10–16) in COPD participants 
(Supplemental Figure 3 and Supplemental Table 1). The signatures 
were also correlated in an additional COPD data set, GLUCOLD 
(demographics in Table 1), in which transcriptomic profiles from 
endobronchial biopsies were obtained from 79 participants with 
COPD (ρ = 0.49, P = 5.0 × 10–6; Supplemental Figure 3 and Sup-
plemental Table 1). Second, we repeated the elastic net procedure 
using SLC26A4, the gene most upregulated with IL-17 stimulation 
in cell culture also measured in the COPD array data (log2 fold 
change = 8.51, FDR = 0), to guide the elastic net. The SLC26A4-
based signature incorporated 16 genes, 6 of which were also in the 
11-gene CCL20-based signature, and was highly correlated with 
the CCL20-based signature in the BAE and GLUCOLD data sets (ρ 
= 0.97 and P < 2.2 × 10–16, ρ = 0.87 and P < 2.2 × 10–16, respectively; 
Supplemental Figure 4 and Supplemental Table 1). Thus, remov-
al of loosely associated genes from the 100-gene signature using 
CCL20 to guide the elastic net measured a response that does not 
appear to be exclusive to CCL20. However, we used the CCL20-
based signature for our subsequent analyses, as it had clear advan-
COPD (n = 152; BAE data set; demographics in Table 1). Candidate 
IL-17 signature genes were enriched among smokers with COPD 
compared with those without (mean of the zero-centered log2 
gene expression in those with COPD = 0.11 ± 0.27 vs. without = 
–0.60 ± 0.19, P = 6.10 × 10–6; Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI121087DS1).
Next, we generated a genomic signature of the IL-17 response 
specific to in vivo brushing samples from smokers by restricting 
the 100-gene signature identified in the culture model to those 
tightly correlated in the BAE data set using an elastic net (34, 35). 
We took this additional step because cell culture models cannot 
optimally reproduce the complexity of the in vivo environment 
in which multiple mechanistic pathways impact gene expression, 
often with disparate effect. This signature refinement process is 
based on the premise that highly intercorrelated genes are coreg-
ulated by the same molecular processes, a premise also used by 
pathway analysis tools such as weighted gene coexpression anal-
ysis (36, 37). Starting with the 100 candidate genes as predictors, 
elastic net regression with leave-one-out cross-validation select-
ed 10 genes highly correlated with a representative IL-17–related 
gene, CCL20, in the BAE data set (Figure 2). We chose CCL20 a 
priori to guide the elastic net gene selection to specifically iden-
tify an IL-17/CCL20–associated response. CCL20 was chosen 
for this role based on (a) biological relevance, as an epithelial 
gene known to be the only ligand for CCR6, a chemokine recep-
tor preferentially expressed by Th17 cells, and thus thought to 
be more specific for an IL-17 response as compared with other 
adaptive immune responses (38); and (b) statistical relevance, 
because it was highly upregulated (log2 fold change = 2.92, FDR 
= 0.0006) following IL-17 stimulation in vitro. Importantly, 
this IL-17–associated gene was chosen to guide gene selection 
because our goal was to retain co-associated genes given their 
Table 1. Demographic characteristics of the 3 data sets
BAE GLUCOLD SPIROMICS
Current and former smokers ± COPD Current and former smokers with COPD;  
subset randomized to placebo or inhaled steroids
Current and former smokers  
with COPD
Smokers n = 151 COPD n = 87 P val. All n = 79 Placebo n = 16 Steroid n = 33 P val. n = 47
Age 65 (6) 64 (6) 0.22 61 (8) 58 (8) 61 (8) 0.22 63 (8)
Smoking status
Current 69 30 0.10 46 14 22 0.79 16
Former 82 57 33 7 15 29
Inhaled steroid use
Yes 7 18 0.0003 0 0 0 NA 17
No 144 69 78 16 33 30
History of asthma
Yes 10 7 0.79 0 0 0 NA 11
No 141 80 78 16 33 33
FEV1% predicted 93 (13) 60 (14) <2.2 × 10
–16 63 (9) 61 (9) 64 (9) 0.28 79 (18)
Means (SD) or total counts are given for continuous and dichotomous variables, respectively. For the BAE data set, P values for differences between 
smokers with and without COPD by Fisher’s exact test or t test as appropriate are given. GLUCOLD and SPIROMICS included only COPD participants, and 
point values are shown for all baseline participants. For GLUCOLD, differences between those randomized to placebo versus inhaled corticosteroid and the 
associated P values are shown.
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In the second data set (GEO GSE53552) (45), biopsies were tak-
en from psoriatic skin lesions and matched nonlesional skin at base-
line (n = 25). Psoriatic lesions were then sampled over 6 weeks after 
treatment with placebo (n = 5) or a dose range of brodalumab (n = 20), 
an IL-17 receptor-α–blocking monoclonal antibody. Psoriatic lesions 
showed higher IL-17 signature expression compared with matched 
nonlesional skin (P = 0.001; Figure 3, C–F). The signature decreased 
over time in psoriatic lesions in those who received 350 or 700 mg 
compared with placebo, but not in those who received 140 mg (350 
mg: P = 0.005 at 1 week, P = 0.02 at 2 weeks, and P = 0.12 at 6 weeks; 
700 mg: P = 0.002 at 2 weeks and 0.0006 at 6 weeks for the interac-
tion between treatment and time; Figure 3, C–F). This was consistent 
with clinical treatment response (all placebo-treated and three of four 
140-mg-treated participants showed no clinical treatment response; 
all 700-mg-treated and all but one 350-mg-treated showed at least 
70% clinical improvement). The observation that our putative IL-17 
signature tracked with clinical response to an IL-17 inhibitor in 2 pso-
riasis clinical trials provides independent confirmation of its value as 
a metric of IL-17–driven inflammation.
Cross-sectional characterization of an IL-17 gene signature in the 
BAE data set. In the BAE data set, our 11-gene IL-17 signature was 
higher in former smokers (mean of the zero-centered log2 gene 
expression = 0.29 ± 0.46) compared with current smokers (–0.42 ± 
0.48, P < 2.2 × 10–16; Figure 4A and Supplemental Table 4), and was 
associated with older age (ρ = 0.19, P = 0.004). The signature was 
increased in COPD compared with ever-smokers without COPD 
(i.e., those with preserved lung function; 0.21 ± 0.66 and –0.12 ± 
0.51, respectively, P = 1.34 × 10–5), even after adjustment for smoking 
status and age (P = 6.2 × 10–6). The signature was also higher with 
decreasing lung function (defined as the volume of air exhaled in the 
first second of a forced expiratory maneuver [FEV1]). Specifically, a 
higher gene signature was associated with lower FEV1 expressed as a 
percentage of the predicted value (FEV1% predicted) across all par-
ticipants (1 unit increase in the IL-17 signature is associated with a 
12-ml decrease in FEV1, P = 1.40 × 10–5) and among only COPD par-
ticipants (associated with a 5.5-ml decrease in FEV1, P = 0.04), sug-
gesting an association with increasing COPD severity (Figure 4B).
Cross-sectional characterization in GLUCOLD and SPIROMICS. 
We next studied baseline clinical characteristics associated with 
the IL-17 signature in GLUCOLD and another COPD data set, SPI-
tages over the others. The asthma signature was generated in a cell 
culture model and never fit to the in vivo environment. SLC26A4 is 
of unclear significance in IL-17 biology, and thus we considered the 
CCL20-based signature more biologically relevant.
IL-17–related gene expression confirmed in an additional air-
way epithelial culture data set. We validated the association 
between the 10 genes selected by elastic net and IL-17 stimula-
tion in another publicly available microarray data set of HBECs 
grown at ALI and stimulated with IL-17 for 24 hours (as opposed 
to the 7-day stimulation in our culture model) (Gene Expression 
Omnibus [GEO] GSE10240) (43). Although 2 of the 10 genes 
(SAA1 and SAA2) were poorly annotated on this array and could 
not be measured, the rest were significantly upregulated after 
IL-17 stimulation in this validation data set (7 of 8 were within 
the top 50 genes by log2 fold change) despite differences in cyto-
kine stimulation time.
IL-17–related gene expression measures a response distinct from 
type 1 and 2 immune responses. Only 3 of the 11 IL-17 signature genes 
were significantly altered after HBECs at ALI were stimulated with 
IFN-γ, the main cytokine released from Th1 and Tc1 cells, and thus 
indicative of a type 1 response. Two of the genes were repressed and 
one induced with an overall mean log2 fold change of –0.19 (Supple-
mental Table 2). None of the genes were significantly upregulated in 
steroid-naive mild to moderate asthmatics previously shown to have 
high type 2 gene expression (n = 40) compared with asthmatics with 
low type 2 expression (n = 22) and healthy controls (n = 43) (Supple-
mental Table 3).
Decreased IL-17 signature expression following IL-17 blockade in 
psoriatic lesions. To further validate that our IL-17 signature reflects 
an IL-17 response, we examined it in 2 publicly available transcrip-
tomic data sets of psoriatic skin lesions before and after controlled 
treatment with anti–IL-17 biologics.
In the first data set (GEO GSE31652) (44), psoriatic skin lesion 
biopsies were taken at baseline and after 2 weeks of ixekizumab, 
an anti–IL-17 monoclonal antibody (n = 6), or placebo (n = 4). All 
ixekizumab-treated participants, but none of the placebo-treated, 
showed clinical improvement of at least 75% at 6 weeks. The skin 
IL-17 gene signature decreased over 2 weeks in lesions from ixeki-
zumab- but not placebo-treated participants (P = 0.003 for the 
interaction between treatment and time; Figure 3, A and B).
Figure 2. Hierarchical clustering of the 11 IL-17 signature genes in the BAE 
data set (n = 237). Signature genes are shown in rows across participants 
in columns. Blue and red indicate low and high relative gene expression, 
respectively. Smokers with and without COPD are indicated by red and 
black, respectively, in the above color bar. Clustering across participants 
and genes was done by Euclidean distance with average linkage.
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Association with increased airway neutrophils and mac-
rophages. In GLUCOLD, the IL-17 signature was associ-
ated with increased airway biopsy neutrophil (P = 6.41 × 
10–5; Figure 5A) and macrophage counts (P = 0.009; Fig-
ure 5B), but not eosinophils, mast cell counts, or our pre-
viously described type 2 genomic signature score (TS2) 
(Table 2). Tissue cell counts and the T2S score were not 
measured in SPIROMICS, but the T2S score was also not 
associated with the IL-17 signature in the BAE data set 
(Table 2). The IL-17 signature was moderately associat-
ed with sputum neutrophil counts in both GLUCOLD (P 
= 0.041; Figure 5C) and SPIROMICS (P = 0.033; Figure 
5D), although this did not stand up to multiple-compari-
sons adjustment. There was no association with sputum 
eosinophil counts or any blood cell counts (Table 2).
Association with airway obstruction. As in the BAE data 
set, in SPIROMICS we found that a higher IL-17 signature 
was associated with slightly greater airway obstruction in 
COPD (P = 0.038 after adjustment for smoking and age; 
Supplemental Figure 5 and Table 3), although this was not 
significant after adjustment for multiple comparisons. In 
GLUCOLD we found a trend toward an association (P = 
0.06 before and P = 0.12 after adjustment for smoking 
and age; Supplemental Figure 5 and Table 3).
Association with CT measurements of functional small airways 
disease. In SPIROMICS, we obtained inspiratory and expiratory 
quantitative chest CT scans at study entry. We found that the 
IL-17 signature was associated with an increase in air trapping 
in areas devoid of emphysema (known as functional small air-
ways disease) by parametric response mapping (PRM) analysis 
(PRMfSAD) (P = 0.01; Figure 6A, Table 3, and ref. 46). The IL-17 
signature was not associated with PRM-measured emphysema 
(PRMemph). However, almost all participants who underwent 
bronchoscopy had mild disease, with very few displaying signif-
icant emphysema (Figure 6B).
ROMICS (demographics in Table 1). GLUCOLD included endo-
bronchial biopsy transcriptomic profiles from steroid-naive partici-
pants with moderate to severe COPD (n = 79). SPIROMICS included 
bronchial epithelial brushing profiles from ever-smokers with mild 
to moderate COPD (n = 47). As in the BAE data set, in both GLU-
COLD and SPIROMICS the IL-17 signature was associated with 
increasing age (ρ = 0.24, P = 0.039, and ρ = 0.20, P = 0.046, respec-
tively) and was higher in former compared with current smokers (P 
= 2.42 × 10–6 and 1.35 × 10–5, respectively; Supplemental Table 4). We 
performed subsequent analyses before and after adjustment for age 
and smoking status.
Figure 3. IL-17 blockade in psoriasis. Ixekizumab: compared 
with placebo (A) (n = 4), the IL-17 signature was decreased in 
psoriatic lesions (n = 6) after 2 weeks of ixekizumab (B). (C–F) 
Brodalumab: Compared with placebo (C) (n = 5), brodalumab (n = 
20) at a dose of 140 mg did not (D), but at a dose of 350 mg (at 1 
and 2 weeks) (E) or 700 mg (at 2 and 6 weeks) (F) did, result in a 
decrease in the IL-17 signature, consistent with clinical response. 
The IL-17 signature was higher in psoriatic lesions than in 
matched nonlesional skin samples (C–F, dashed lines). *P < 0.05 
using mixed-effects models.
Figure 4. Clinical correlations in the BAE dataset. The IL-17 gene signature 
in the BAE data set (n = 237) was increased in former (0.29 ± 0.46) com-
pared with current smokers (–0.42 ± 0.48, P < 0.001 by Wilcoxon rank sum 
test) (A), and associated with decreasing FEV1% predicted (ρ = –0.23, P < 
0.001 by Spearman’s correlation) (B).
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
1 7 4 jci.org   Volume 129   Number 1   January 2019
Association with decreased response to inhaled corticosteroids 
in GLUCOLD. Following baseline bronchoscopy in GLUCOLD, 
49 participants with available baseline biopsies were ran-
domized to treatment with 30 months of medication contain-
ing inhaled corticosteroid (ICS) (n = 33) or placebo (n = 16). 
A higher baseline IL-17 signature was associated with lack of 
improvement in post-bronchodilator FEV1 on ICS, whereas a 
lower IL-17 signature was associated with improvement in 
FEV1, as compared with placebo (P = 0.028 for the interac-
tion between treatment and time; Figure 7 and Table 3). We 
identified 28% of GLUCOLD participants as having high IL-17 
gene expression (“IL-17–high”) by cluster partitioning (31% of 
Figure 5. Airway neutrophils and macrophages. (A–C) GLUCOLD (n = 79): The IL-17 signature was associated with increasing log2 counts of airway tissue 
neutrophils (A), airway tissue macrophages (B), and sputum neutrophils (C) (n = 72 with measured neutrophils). (D) SPIROMICS: The signature was associ-
ated with log2 sputum neutrophil counts (n = 20). P values shown for linear models adjusted for age and smoking status.
Table 2. Association between IL-17 metric and cell counts or T2S score
Unadjusted Adjusted
R2 Coefficient (SE) P val. FDR R2 Coefficient (SE) P val. FDR
Neutrophils
GLUCOLD
Endobronchial neutrophils 0.19 0.27 ( 0.06) 6.41 × 10–5 <0.001 0.20 0.26 (0.07) 0.0008 0.002
Sputum neutrophils 0.14 0.34 (0.10) 0.001 0.002 0.17 0.27 (0.13) 0.041 0.061
Blood neutrophils (%) 0.002 –0.83 (2.00) 0.68 0.68 0.08 0.57 (2.26) 0.80 0.80
SPIROMICS
Sputum neutrophils 0.14 0.33 (0.19) 0.10 0.20 0.37 0.44 (0.19) 0.033 0.066
Blood neutrophils 0.005 –0.02 (0.03) 0.63 0.63 0.09 0.03 (0.04) 0.43 0.43
Macrophages
GLUCOLD
Endobronchial macrophages  0.13 0.22 (0.06) 0.0009 0.002 0.14 0.20 (0.07) 0.009 0.019
Sputum macrophages 0.008 0.07 (0.09) 0.45 0.45 0.03 –0.02 (0.11) 0.84 0.84
SPIROMICS
Sputum macrophages 0.008 0.05 (0.13) 0.71 NA 0.02 0.06 (0.14) 0.68 NA
Eosinophils
GLUCOLD
Endobronchial eosinophils 0.02 0.11 (0.10) 0.28 0.35 0.01 0.02 (0.12) 0.87 0.923
Sputum eosinophils 0.01 0.09 (0.08) 0.31 0.35 0.05 –0.01 (0.11) 0.92 0.923
Blood eosinophils 0.01 0.32 (0.34) 0.35 0.35 0.10 –0.21 (0.39) 0.59 0.923
SPIROMICS
Sputum eosinophils 0.11 0.46 (0.40) 0.27 0.31 0.56 0.40 (0.41) 0.35 0.35
Blood eosinophils 0.02 0.07 (0.07) 0.31 0.31 0.07 0.12 (0.08) 0.15 0.30
Mast cells
GLUCOLD
Endobronchial mast cells 0.007 –0.03 (0.04) 0.47 NA 0.01 –0.02 (0.05) 0.67 NA
T2S score
BAE 0.05 –1.49 (0.71) 0.039 NA 0.10 –0.94 (0.85) 0.27 NA
GLUCOLD 0.04 –1.01 (0.60)  0.096 NA 0.14 –0.16 (0.67) 0.82 NA
“Adjusted” models adjusted for smoking status and age. Count values for endobronchial tissue and sputum samples were logged prior to analysis. False 
discovery rates (FDRs) were calculated on a cell type–specific basis over each study. Cell counts associated with the IL-17 signature at P value <0.05 across 
both studies shown in bold.
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COPD participants over all 3 studies, including 33% of BAE 
and 34% of SPIROMICS participants, were IL-17 high; Supple-
mental Figure 6). After categorization of participants based on 
this cluster partitioning, those with an “IL-17–low” designa-
tion were more likely to respond to ICS with an improvement 
in lung function, while IL-17 high was associated with lack of 
response to ICS at 30 months (P = 0.047 for the interaction 
between IL-17 status and percentage change in FEV1 after ICS 
compared with placebo).
We found that a high IL-17 signature was specific but not sen-
sitive for steroid unresponsiveness. Using the dichotimization into 
IL-17 high and low by cluster partitioning, the specificity for ste-
roid unresponsiveness was 75% (Supplemental Table 5). When the 
IL-17–high group was restricted to a slightly higher cutoff at the top 
quartile of IL-17 signature values, the specificity increased to 94% 
(Supplemental Table 6).
The association between the IL-17 signature and change in 
FEV1 among ICS-treated participants was not due to those partic-
ipants with low IL-17 signature expression reciprocally exhibiting 
high type 2 inflammation. The significance of the relationship 
between the IL-17 signature and ICS response persisted even after 
we adjusted for markers of steroid-responsive type 2 inflammation 
using either airway tissue eosinophils (P = 0.027) or our previously 
identified airway epithelial genomic signature of type 2 inflamma-
tion (P = 0.018; Supplemental Figure 7, Table 3, and ref. 6). The 
association also does not appear to be explained by IL-17 inflam-
mation simply reflecting tissue neutrophils or macrophages, as 
adjustment for neutrophil or macrophage counts in the model also 
did not change the relationship between the IL-17 signature and 
ICS response (P = 0.016 and 0.030, respectively; Table 3).
The IL-17 signature alone explained 23% of the variation in 
change in FEV1 with corticosteroids (r2 = 0.23; Table 3). As expect-
ed given the low sensitivity of the IL-17 signature for steroid unre-
sponsiveness, the area under the receiver operating characteristic 
curve (AUC) was modest (63%; Supplemental Figure 8). However, 
there were no significant associations between other biomarkers 
of inflammation (including sputum and blood cell counts) and 
change in FEV1 in ICS- versus placebo-treated participants after 
adjustment for age and smoking status. Furthermore, the AUCs 
for these other potential biomarkers (sputum eosinophils, 51%; 
blood eosinophils, 55%; sputum neutrophils, 52%; blood neutro-
phils, 45%) suggest that they lack any predictive power for corti-
costeroid responsiveness in this data set (Supplemental Figure 
Table 3. Association between IL-17 metric and clinical parameters in COPD participants
Unadjusted Adjusted
R2 Coefficient (SEM) P val. FDR R2 Coefficient (SEM) P val. FDR
Baseline
BAE
FEV1% predicted 0.01 –2.34 (2.28) 0.31 NA 0.09 –5.52 (2.68) 0.042 NA
GLUCOLD
FEV1% predicted 0.04 –3.40 (1.81) 0.064 NA 0.07 –3.23 (2.10) 0.129 NA
SPIROMICS
FEV1% predicted
A 0.03 –2.50 (2.1) 0.23 0.35 0.13 –5.24 (2.44) 0.038B 0.057
CT PRMemph A 0.03 0.61 (0.65) 0.35 0.35 0.08 0.78 (0.91) 0.40 0.40
CT PRMfSAD A 0.12 3.40 (1.57) 0.037 0.11 0.26 5.70 (2.07) 0.0097B 0.029
Longitudinal
GLUCOLD: change over 30 months after inhaled steroid treatment compared with placebo (n = 48)
FEV1% 0.23 –0.014 (0.009) 0.11 NA 0.36 –0.019 (0.008) 0.024 NA
FEV1% also adjusted for airway tissue eosinophils NA NA NA NA 0.36 –0.020 (0.009) 0.027 NA
FEV1% also adjusted for T2S score NA NA NA NA 0.38 –0.020 (0.008) 0.018 NA
FEV1% also adjusted for airway tissue neutrophils NA NA NA NA 0.3 –0.022 (0.009) 0.016 NA
FEV1% also adjusted for airway tissue macrophages NA NA NA NA 0.36 –0.019 (0.008) 0.030 NA
“Adjusted” models adjusted for smoking status and age. FEV1% predicted, forced expiratory volume in 1 second, percent predicted; NA, not applicable; 
PRMemph, parameteric response mapping emphysema biomarker; PRMfSAD, parameteric response mapping functional small airways disease biomarker; 
T2S, type 2 signature. AParameters adjusted for multiple comparisons; BP value adjusted for FDR < 0.1. P values <0.05 shown in bold.
Figure 6. CT biomarkers. The IL-17 signature was associated with 
increasing percentage of lung area with functional small airways disease 
(PRMfSAD) (A) but not emphysema (PRMemph) (B) by parametric response 
mapping of baseline CT scans (n = 35). P values shown for linear models 
adjusted for age and smoking status.
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related inflammation within COPD (13, 25–30), and our data sug-
gest that this variability is clinically significant. Other studies have 
identified some characteristics of IL-17–associated inflammation 
in COPD, including more severe obstruction, emphysema, and 
lymphoid neogenesis (13, 15). Here we comprehensively investi-
gated the associations between IL-17–driven inflammation and 
COPD patient characteristics. In addition to an association with 
increased airway obstruction, we found associations with a novel 
CT biomarker of functional small airways disease and corticoste-
roid unresponsiveness. COPD phenotypes are heterogeneous and 
complex. Thus we hypothesize that multiple overlapping molec-
ular phenotypes underlie the complex clinical phenotypes we 
observe in chronic airway diseases and that there will be an upper 
bound to the predictive power of any one biological pathway (33, 
49). However, a strength here is that we observe correlations that 
are reproducible across our transcriptional data sets (for associa-
tions with neutrophils and FEV1).
We had hypothesized that the IL-17 signature would be asso-
ciated with increased emphysema, as found in a previous study 
(13). We evaluated this using the recently developed PRM CT 
analysis method (46). By matching inspiratory and expirato-
ry scans, PRM improves the ability to distinguish emphysema 
from functional small airways disease, both of which are asso-
ciated with low-radiodensity lung regions on expiration (i.e., air 
trapping). Our IL-17 signature is associated with PRMfSAD but 
not PRMemph in SPIROMICS. As the participants generally had 
mild to moderate disease with minimal emphysema, the lack of 
association with PRMemph is not surprising. The association with 
PRMfSAD is of interest as the small airways are likely the main site 
of airway inflammation in COPD, and small airways disease is 
thought to precede emphysema (50). Studies using PRM have 
supported these findings. PRMfSAD is associated with more rap-
id FEV1 decline, particularly in mild to moderate disease (47). 
PRMfSAD is also the greater contributor to radiographic abnor-
malities in mild to moderate COPD, with both PRMfSAD and 
PRMemph contributing in severe disease (46). Thus, an associa-
tion between our IL-17 signature and PRMfSAD in mild to mod-
erate COPD does not preclude an association with emphysema 
in more severe disease. In fact, it signifies an association with a 
more severe phenotype among participants with milder airway 
obstruction and suggests that IL-17–related inflammation may 
be a pathway on which to intervene to prevent the progression to 
emphysema and severe airway obstruction.
Our IL-17 signature, when measured at baseline, is associ-
ated with a poor lung function response to corticosteroids at 30 
8). Although limited by small sample size, these proof-of-con-
cept analyses suggest that our airway epithelial signature of IL-17 
response in COPD may mark FEV1 response to ICS better than 
easily measured cell differentials or other genomic markers of the 
adaptive immune response.
Discussion
In this study, we used 3 complementary human COPD studies 
to characterize the clinical significance of the airway epithelial 
response to IL-17 in COPD. We showed that a signature of IL-17–
associated airway inflammation is upregulated in a subset of par-
ticipants with COPD (31% across studies), and is associated with 
distinct inflammatory, physiologic, and clinical features. Increases 
in this signature are associated with an inflammatory profile char-
acteristic of an IL-17 response, including increased airway neutro-
phils and macrophages but not eosinophils, type 2 markers, or type 
1 gene expression. Decreases in the signature occur in response to 
therapeutic blockade of IL-17 in psoriatic skin lesions, and this 
response corresponds to clinical improvement in that disease. In 
COPD, the signature is further associated with more severe airway 
obstruction and a novel CT biomarker of functional small airways 
disease that is predictive of worsening airway disease over time 
(46, 47). Finally, higher IL-17 signature expression is associated 
with a lack of response to ICS in COPD, whereas low expression 
may identify those patients who benefit from ICS. This association 
does not appear to be due simply to reciprocal alterations in type 2 
inflammation, as the interaction between our IL-17 signature and 
treatment was unaffected by adjustments for airway eosinophils 
or our type 2 airway genomic signature. Thus, our findings suggest 
that enhanced IL-17 inflammation characterizes a distinct subset 
of COPD, and that identifying this subgroup may be important for 
therapeutic decisions.
In COPD, chronic exposure to smoking, microbial insults, and 
recurrent mucosal injury may all contribute to immune activation 
with IL-17–producing T cells, supported by innate IL-17–producing 
cells (17). This likely contributes to ongoing neutrophilic inflamma-
tion and macrophage recruitment with subsequent airway remod-
eling and tissue destruction (48). We found that our IL-17 gene 
expression signature is associated with increases in airway neutro-
phils and macrophages, indicating an IL-17 response. It is related to 
worse clinical outcomes across former and current smokers. These 
findings provide evidence for the contribution of IL-17 inflamma-
tion to COPD pathology despite smoking cessation.
We found that the IL-17 response in COPD is heterogeneous, 
enhanced in a subgroup. Prior studies found variability in IL-17–
Figure 7. ICS response in GLUCOLD. An increased baseline IL-17 signature 
was associated with a greater decrease in percentage change in FEV1 in the 
ICS ± long-acting β-agonist group (n = 33) compared with placebo (n = 16) 
at 30 months (P = 0.024 for the linear model interaction with adjustment 
for age and smoking status). Participants with low IL-17 signatures were 
more likely to show an improvement in FEV1 after ICS (greater than zero: 
above the dashed line).
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only show associations, not causality. Our longitudinal anal-
yses were limited by sample size. Thus, while we did find a 
strong association between our IL-17 signature and lack of 
response to inhaled steroids over 30 months, an assessment of 
the predictive power of the signature for corticosteroid respon-
siveness was quite limited. Furthermore, our definitions of 
“high” and “low” for the IL-17 signature are highly dependent 
on the population in which they were developed. Therefore, 
further studies will be needed to determine whether the signa-
ture could be used as a biomarker for steroid unresponsiveness, 
and to determine the best cutoff for IL-17 high and low. We also 
were not powered to study the association between the signa-
ture and exacerbation rates, which will be important to study in 
relation to therapeutic response. It was not within the scope of 
this study to identify the cause of the increased IL-17 response. 
We do, however, see associations in current and former smok-
ers, suggesting that more than just smoke exposure is playing 
a role. The contributions of stimuli such as alterations in the 
microbiome or autoimmunity to enhanced IL-17–related gene 
expression will require further study. Furthermore, COPD phe-
notypes are heterogeneous and complex, and thus we hypoth-
esize that multiple overlapping molecular phenotypes underlie 
the complex clinical phenotypes we observe in chronic airway 
diseases. Finally, future work will be needed to identify surro-
gate biomarkers in more easily obtained specimens than airway 
brushings. This is similar to the approach we took in our asth-
ma studies in which we initially identified a type 2 high asthma 
molecular phenotype based on airway gene expression, and 
then expanded this work to identify the best associated bio-
markers (periostin, eosinophils, FeNO).
In summary, we show here that a signature of IL-17–associated 
airway inflammation is upregulated in approximately a third of 
COPD participants and is associated with distinct inflammatory, 
physiologic, and clinical features. Our findings suggest that the 
IL-17 signature defines a molecular COPD phenotype that responds 
poorly to corticosteroid therapy, and that could instead be the target 
of emerging therapies that interfere with IL-17 (44, 45, 48).
Methods
Transcriptomic data sets
Eight transcriptomic data sets were used for these analyses:
UCSF human bronchial epithelial cell culture data set. Human bronchi-
al epithelial cells (HBECs) obtained from the proximal airways of 6 lung 
donors rejected for transplant (5 without airway disease, 1 with asthma) 
were grown to confluence in an air-liquid interface (ALI) culture for 28 days 
as described previously (54). Some cultures were stimulated with IL-17 (10 
ng/ml) for the final 7 days of culture or IFN-γ (10 ng/ml) for the final 24 
hours of culture. Matched cultures maintained in media without cytokine 
over the same time period were used as controls. Cultured cells were then 
harvested and underwent RNA isolation using the Qiagen miRNeasy kit 
(Qiagen Inc.) per the manufacturer’s protocol. RNA quality and quantity 
were assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies) 
and the NanoDrop Spectrophotometer (Thermo Fisher Scientific). Library 
preparation and multiplexing were done using the Illumina TruSeq Strand-
ed Total RNA with Ribo-zero Human/Mouse/Rat kit (Illumina Inc.) per 
the manufacturer’s protocol at the UCSF Sandler Genomics Core Facility. 
months. This corticosteroid responsiveness is not simply due 
to participants with low IL-17 signature expression exhibiting 
low neutrophil counts or reciprocally exhibiting high type 2 
inflammation. In murine models, Th17 cell–mediated airway 
inflammation has been shown to be corticosteroid resistant, 
in contrast to Th2 cell–mediated inflammation (51). Here, 
for the first time to our knowledge, we show the association 
between an IL-17 inflammatory signature and corticosteroid 
unresponsiveness in a longitudinal randomized controlled trial 
in humans. Many patients with COPD do not respond to corti-
costeroids, and ICSs are only indicated in exacerbation-prone 
symptomatic COPD. However, corticosteroids are still used 
broadly despite possible increases in adverse outcomes such as 
pneumonia (52). The corticosteroid unresponsiveness finding 
suggests that a more easily measurable surrogate for our IL-17 
signature could serve as a biomarker for therapeutics in COPD. 
While it may be useful to predict who will not respond to cor-
ticosteroids, it may be even more useful to predict who will 
respond to therapies targeting IL-17 or associated inflammatory 
pathways as we found in psoriatic lesions.
Our study relied on the airway epithelial gene expression 
response to IL-17. The airway epithelium is the first line of defense 
against injury in the lung and a chief target on which IL-17 induces 
an effect. Other studies have relied on cell counts or immunoreac-
tivity, which are poorly correlated in the human lung (13). Addition-
ally, Th17 cells display a high level of plasticity, and are thus more 
unstable than Th1 or Th2 cells (53), suggesting that cell numbers 
may not represent cytokine response. Data are also conflicting on 
whether IL-17+ cell counts are elevated in COPD and related to key 
pathologic characteristics such as airway neutrophilia (28, 29). We, 
however, show that IL-17 signature genes are not only upregulated 
in 2 separate experiments in which HBECs were stimulated with 
IL-17, but that our signature is associated with increases in airway 
neutrophils as well. We also show that our signature is decreased in 
response to IL-17–blocking agents in psoriatic skin lesions but dis-
tinct from airway epithelial type 1 and 2 responses, further indicat-
ing that we are marking an IL-17–specific epithelial response.
We acknowledge that fitting our IL-17 signature to CCL20 
could have limited its generalizability. However, the signature gen-
eralized well in that (a) it was highly correlated with 2 other IL-17 
gene signatures (a signature previously studied in asthma [ref. 39] 
and a signature fit to SLC26A4, the most significantly upregulated 
gene in our IL-17–stimulated human bronchial epithelial culture 
experiments) and (b) our IL-17 signature was responsive to anti–
IL-17 therapy and reflective of clinical response in 2 randomized 
controlled trials in psoriasis. The advantage of fitting this gene 
signature to CCL20 is that it improved its “fit” to a more complex 
in vivo tissue environment rather than a simple cell culture mod-
el. In a COPD patient this complex environment may be further 
compounded by multiple airway insults (e.g., smoking, microbial 
colonization, exacerbations, medications) that are not modeled 
well in culture. By retaining only tightly intercorrelated genes, a 
well-established method for identifying genes in the same molec-
ular pathway (36, 37), we removed those genes that may be non-
specific to an IL-17 response in vivo.
Our study has some potential limitations. For instance, 
some analyses were cross-sectional, and those analyses can 
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At least a 20-pack-year smoking history was required for inclu-
sion, and participants were classified as former smokers after 1 year 
of smoking cessation. Participants were classified as having COPD 
based on spirometry, performed before and after 4 inhalations each 
of albuterol (90 μg dose per inhalation) and ipratropium (18 μg dose 
per inhalation), using the GOLD staging system (58). Full inclusion/
exclusion criteria are included in Supplemental Table 7.
Blood collection, sputum induction, and CT scans were done at 
the first study visit. Sputum induction was performed as previously 
described (59). Parametric response mapping (PRM) of CT imaging 
was used to distinguish areas of normal lung (PRMnorm) from areas of 
functional small airways disease (PRMfSAD) and emphysema (PRMemph) 
as previously described (46, 47). Briefly, PRM is a CT voxel-based 
imaging biomarker that uses dynamic image registration to spatial-
ly align paired inspiratory and expiratory scans. PRMfSAD is defined 
as areas of lung that are greater than –950 Hounsfield units (HU) on 
inspiration and less than –856 HU on expiration. PRMemph is defined as 
areas of lung that are less than –950 HU on inspiration and less than 
–856 HU on expiration. PRMnorm is defined as areas of lung exceeding 
both thresholds on inspiration and expiration.
Derivation of gene expression data sets
RNA-Seq (HBEC culture data set). FASTQ files were quality-filtered and 
aligned to the human genome using STAR and the Ensembl GRCh38 
genome build (60, 61). Read counts were normalized and differential 
expression analyses on matched samples were performed between 
(a) IL-17–stimulated samples and controls and (b) IFN-γ–stimulated 
samples and controls using the DESeq2 package in R (62). Differential 
expression in DESeq2 is carried out using generalized linear models 
following a negative binomial distribution. Results were trimmed to 
transcripts indexed in the HUGO Gene Nomenclature Committee 
(HGNC) database and with an Ensembl gene biotype label of “pro-
tein_coding.” Multiple-comparisons corrections were done using false 
discovery rate (FDR) by the Benjamini-Hochberg method (63).
Microarray (BAE, asthma, GLUCOLD, ixekizumab, and brodalumab 
data sets). Each microarray data set independently underwent back-
ground adjustment (without the use of mismatch probes), quantile nor-
malization, and probe summarization using the RMA algorithm (affy 
package, Bioconductor, R) (64, 65). Entrez Gene custom chip defini-
tion files available for the appropriate microarray for each data set at 
http://brainarray.mbni.med.umich.edu were used for annotation. 
Batch effect was minimized using Combat when appropriate (66).
Quantitative PCR (SPIROMICS data set). Data were normalized to 
the mean of PPIA, RPL13A, ACTB, and DNAJA1, determined using the 
SLqPCR package in R, as described previously (32, 67).
Derivation of the IL-17 genomic signature
An IL-17 genomic signature specific to bronchial epithelial brushings 
from smokers was generated using elastic net regression for feature 
selection in the BAE data set. The 100 genes most upregulated in ALI 
models after IL-17 stimulation were used as candidate predictor vari-
ables (“features”). Genes highly correlated with a representative IL-17 
gene, CCL20, were selected as features for inclusion in the IL-17 sig-
nature using elastic net regression via the glmnet package in R with 
α = 0.75 and leave-one-out cross-validation (68). Alpha was selected 
at just below 1 to maximize sparsity (and thus limit feature selection) 
while allowing for selection of closely correlated genes. CCL20 and 
One-hundred-base-pair paired-end sequencing was done on multiplexed 
samples via the Illumina HiSeq 2500 at the UCSF Genomics Core.
Bronchial airway epithelial data set. Bronchial epithelial brushings 
obtained from sixth- to eighth-generation bronchi of former and cur-
rent smokers with a range of lung function (COPD, 85; no COPD, 152) 
were previously profiled by Affymetrix HG 1.0 ST Arrays (55). Spirome-
try was done in all participants. Raw microarray files may be download-
ed from the Gene Expression Omnibus (GEO; accession GSE37147) 
(54). Inclusion/exclusion criteria were previously published.
Validation HBEC culture data set. Data were downloaded from 
GEO (GSE10240). Primary HBECs provided by the Tissue Core Labo-
ratory at the University of Pittsburgh (Pittsburgh, Pennsylvania, USA) 
or purchased from Cambrex (Lonza) were grown to confluence in ALI, 
then stimulated apically and basolaterally with media control or IL-17 
for 24 hours (3 replicates each) as previously described (43). Isolated 
RNA was profiled by Affymetrix HG U133A 2.0 Arrays.
Asthma data set. Bronchial airway epithelial (BAE) brushings obtained 
by bronchoscopy from steroid-naive subjects with mild to moderate asth-
ma (n = 62) and control subjects without asthma (n = 43) were previously 
profiled by Affymetrix HG U133 Plus 2.0 Arrays (GEO GSE67472) (24). 
Inclusion/exclusion criteria for this study were previously published (24). 
Subjects with asthma were divided into type 2–high and –low subgroups 
(n = 40 and 22, respectively) using a validated standardized mean expres-
sion level of POSTN, SERPINB2, and CLCA1 (24, 32). IL-17–associated 
genes were evaluated among those differentially expressed between type 
2–high asthma and type 2–low asthma and healthy controls.
Ixekizumab psoriasis data set. Data were downloaded from GEO 
(GSE31652). Biopsies of psoriatic skin lesions were taken at baseline 
and after treatment for 2 weeks with ixekizumab (n = 6) or placebo (n 
= 4) and previously profiled by Affymetrix HG U133A 2.0 Arrays (44).
Brodalumab psoriasis data set. Data were downloaded from GEO 
(GSE53552). Biopsies were taken from psoriatic skin lesions and 
matched nonlesional skin from 25 participants at baseline. The psori-
atic lesions were then sampled over 6 weeks after treatment with pla-
cebo (n = 5) or a dose range of brodalumab (140 mg, n = 4; 350 mg, n = 
8; 700 mg, n = 8). All samples were previously profiled by Affymetrix 
HG U133 Plus 2.0 Arrays (45).
Groningen and Leiden Universities Study of Corticosteroids in 
Obstructive Lung Disease (GLUCOLD) data set. Endobronchial biopsies 
from steroid-naive participants with moderate to severe COPD (n = 
79) were previously obtained by bronchoscopy and profiled by Affy-
metrix HG 1.0 ST Arrays (GEO GSE36221) (56). Blood collection, 
sputum induction, and spirometry were done at the first study visit via 
previously described methods (57). A subset of these participants was 
randomized to receive 30 months of placebo (n = 16) or ICS with or 
without long-acting β-agonist (salmeterol) (n = 33). Inclusion/exclu-
sion criteria were previously published (57).
Subpopulations and Intermediate Outcome Measures in COPD Study 
(SPIROMICS) data set. A subgroup of participants in the SPIROMICS 
multicenter observational cohort study underwent research bron-
choscopy. RNA was obtained from bronchial epithelial brushings 
from third- to fourth-generation bronchi of the right or left lower 
lobe of current and former smokers with mild to moderate COPD (n 
= 47). RNA was used for profiling IL-17–associated gene expression 
by 2-step, nested-primer quantitative reverse transcription PCR as 
described previously (32). Primer and probe sequences are listed in 
Supplemental Table 8.
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IL-17 signature genes, based on a majority vote of 30 indices that evalu-
ate partitioning (70). NbClust deals with the inherent variability in the 
many indices available to determine the optimal number of clusters by 
requiring a consensus vote among these indices on best partitioning. 
Participants with relatively high expression who clustered separately 
from the majority of participants were considered “IL-17 high.” Before 
determination of the best number of partitions, the data sets were first 
stratified by smoking status given the large effect of smoking on gene 
expression. Differences among indices in deciding best clustering 
were generally due to separation of those with IL-17–high expression 
into 1 or more categories, while those with low expression clustered 
together. The exceptions were 2 participants in the SPIROMICS data 
set with low expression that were partitioned into their own groups. 
Six of 35 participants with relatively high IL-17 gene expression in the 
BAE data set, 3 of 23 participants in the GLUCOLD data set, and 5 of 
18 participants in the SPIROMICS data set were partitioned out as the 
highest for IL-17 expression. For simplicity, all IL-17 high, including 
these highest participants, were grouped together.
The IL-17 signature was then discretized into 2 categories, IL-17 
high and IL-17 low, using 2 different methods, to use as a categorical 
predictor for longitudinal analyses in GLUCOLD. Discretization was 
first based on the best partitioning decided by NbClust, and then alter-
natively based on the top quartile of signature expression. Ten percent 
of samples with IL-17 signatures closest to the partition were removed 
before discretization to diminish overlap.
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the 10 genes selected by elastic net regression were used for genera-
tion of the IL-17 signature. The mean of the zero-centered log2-scale 
gene expression values of these 11 genes was used as the IL-17 airway 
epithelial signature metric, a previously validated method (33, 39). To 
confirm that our IL-17 signature was not just specific to CCL20, two 
alternative IL-17 signatures were generated. One was generated using 
the above procedure with SLC26A4, the most upregulated gene fol-
lowing IL-17 stimulation in cell culture also measured in the COPD 
array data, guiding the elastic net. The other was an IL-17 signature 
previously studied in asthma and was generated in the same way as 
previously reported, using the mean value of the zero-centered gene 
expression of five IL-17–associated genes (39).
For the ixekizumab and brodalumab studies, 4 genes were exclud-
ed before derivation of the IL-17 signature metric: 2 genes that were 
poorly annotated in the microarray platform used (SAA1, SAA2) and 
2 genes that were not expressed above background (CSF3, MTNR1A1) 
in these skin biopsies. As there was 100% concordance between the 2 
psoriasis studies on genes not expressed above background, we con-
cluded that these genes were poorly expressed in the resident skin 
cells. We did not, however, change the signature in any way based on 
knowledge of the genes or relevance in psoriasis. The IL-17 skin sig-
nature was thus derived using the mean value of the zero-centered 
log2-scale gene expression values of the remaining 7 genes (CCL20, 
SLC26A4, TNIP3, CXCL3, CXCL5, CXCL6, and VNN1).
Statistical analyses of the IL-17 genomic signature
All regression analyses were performed using the limma package in 
R (69). For cross-sectional analyses of the associations between the 
IL-17 signature and clinical variables (in the BAE, GLUCOLD, and SPI-
ROMICS data sets), linear or logistic regression was used, as appro-
priate. Analyses were done before and after adjustment for age and 
smoking status. Race, sex, pack-years, and ICS use were evaluated as 
potential confounders as well. These variables were, however, left out 
of the final models, as they were not significantly associated with IL-17 
signature expression, and did not significantly alter the relationships 
between the IL-17 signature and outcomes beyond adjustments for 
age and smoking status. Data were transformed when necessary for 
normal distribution. A P value less than 0.05 was considered signif-
icant. However, multiple-hypothesis testing was done using an FDR 
when appropriate (63). For the ixekizumab and brodalumab studies, 
mixed-effects models were used to relate the IL-17 signature (as the 
outcome variable) to the interaction between treatment and time 
(fixed effects) across participants (random effect). For longitudinal 
analyses in GLUCOLD, the interaction between treatment (ICS or pla-
cebo) and the baseline IL-17 signature was related to change in FEV1 
over 30 months. The ICS and ICS plus long-acting β-agonist groups 
were combined to improve power, as the long-term effects in these 
groups were comparable. In secondary analyses, the interactions 
between the IL-17 score and (a) tissue eosinophils, (b) our previously 
generated metric of type 2 inflammation (the T2S score), or (c) tissue 
neutrophils were related to change in FEV1 over 30 months among 
those GLUCOLD participants who received ICS (6).
Clustering
All clustering analyses were performed using Euclidean distance with 
average linkage as the distance metric. The NbClust package (Biocon-
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